Genomic Health (GHDX) Tops Q4 EPS by 2c, FY15 EPS Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts GHDX Hot Sheet
Join SI Premium – FREE
Genomic Health (NASDAQ: GHDX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $69.1 million versus the consensus estimate of $72.2 million.
Genomic Health sees FY2015 EPS of ($0.53)-($0.75), versus the consensus of ($0.52). Genomic Health sees FY2015 revenue of $292-305 million, versus the consensus of $310.61 million.
For earnings history and earnings-related data on Genomic Health (GHDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chegg (CHGG) Misses Q3 EPS by 1c ; Offers Guidance
- Syra Health Corp. (SYRA) Reports Q3 EPS of $0.02
- Sysco Corp. (SYY) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
